Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW9ML8
|
|||
| Drug Name |
LMB763
|
|||
| Synonyms |
Nidufexor; 1773489-72-7; LMB-763; UNII-CJ1PL0TE6J; CJ1PL0TE6J; 4-[(N-benzyl-8-chloro-1-methyl-1,4-dihydro[1]benzopyrano[4,3-c]pyrazole-3-carboxamido)methyl]benzoic acid; Nidufexor [INN]; CHEMBL4297626; SCHEMBL16702097; GTPL10655; BCP28929; EX-A1854; Nidufexor pound LMB-763 pound(c); BDBM50527021; MFCD31657267; ZINC584641402; compound 1 [PMID: 31940200]; 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid; BS-15605; HY-109096; CS-0039398; Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(O)=O)c2COc3ccc(Cl)cc3-c12; 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid; Benzoic acid, 4-((((8-chloro-1,4-dihydro-1-methyl(1)benzopyrano(4,3-C)pyrazol-3-yl)carbonyl)(phenylmethyl)amino)methyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [1] | |
| Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 2 | [2] | ||
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H22ClN3O4
|
|||
| Canonical SMILES |
CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O
|
|||
| InChI |
1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
|
|||
| InChIKey |
JYTIXGYXBIBOMN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1773489-72-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Farnesoid X-activated receptor (FXR) | Target Info | Agonist | [3] |
| KEGG Pathway | Bile secretion | |||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Recycling of bile acids and salts | |||
| PPARA activates gene expression | ||||
| Endogenous sterols | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Nuclear Receptors Meta-Pathway | ||||
| Farnesoid X Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03804879) Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02913105) Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH. U.S. National Institutes of Health. | |||
| REF 3 | Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.